- Company
- Emerging Chinese company BeiGene readies for Korean market
- by Eo, Yun-Ho Dec 8, 2020 06:12am
- A China-based emerging pharmaceutical company, BeiGene is readying for the South Korean market. The pharmaceutical industry sources reported the Chinese company has opened a South Korean subsidiary recently. The company has already recruited Head of Medical Affairs Kim Jiyoon, previously worked in medical affairs at Sanofi Genzyme, and t
- Company
- Coverage expansion this year 70% less than last year
- by Eo, Yun-Ho Dec 8, 2020 06:11am
- Apparently, the number of new drug reimbursement expansion has gone down significantly this year. Daily Pharm surveyed the pharmaceutical reimbursement status from 2019 to 2020 and found the number of reimbursement expansion dropped 70 percent and 75 percent by indication compared to last year. The statistic data includes reimbursement e
- Company
- Roche Xofluza to be prescribed for flu prevention in Korea
- by Eo, Yun-Ho Dec 8, 2020 06:11am
- The prescription of a next-generation influenza new drug Xofluza is to get accessible in South Korea for prevention purpose. According to the pharmaceutical industry sources, Roche Korea applied for approval on Xofluza to the Ministry of Food and Drug Safety (MFDS) after the drug’s new indication to prevent influenza was cleared by the
- Policy
- Xultophy Flex Touch pen·Afstyla can be reimbursed
- by Lee, Hye-Kyung Dec 8, 2020 06:11am
- Novo Nordisk's Xultophy Flex Touch pen (Insulin Degludec and Liraglutide) and CSL Behring's Afstyla (Antihemophilic Factor) were set higher in the amount applied by pharmaceutical companies compared to the adequacy evaluation of Benefits. The HIRA (President Kim Sun-min) released the results of the deliberation on the adequacy of medical
- Policy
- Benefit redemption of α-GPC will be promoted soon
- by Lee, Hye-Kyung Dec 7, 2020 06:06am
- As the clinical re-evaluation of Choline alfoscerate is imminent, the NHIS' benefit redemption contract is expected to be pursued sooner or later. The consortium of Daewoong and Chong Kun Dang On the 1st of the month, an online briefing session for clinical reevaluation was held, and it was announced that it would recruit pharmaceutical co
- Company
- Daewoong succeeded in evading patent for Belkyra
- by Kim, Jin-Gu Dec 7, 2020 06:06am
- Daewoong has passed the final gateway for the early release of a generic for Belkyra (Deoxycholic acid), an injection for improving submandibular fat. The original company Allergan succeeded in avoiding the remaining one of the two divisional patents. According to the pharmaceutical industry on the 3rd, the Intellectual Property Trial
- Policy
- SB16 has been approved for phase III clinical trial
- by Lee, Tak-Sun Dec 7, 2020 06:06am
- Samsung Bioepis is the first in Korea to enter Phase III clinical trial of Prolia's biosimilar, an osteoporosis treatment. The MFDS approved the Phase III clinical trial protocol for a biosimilar candidate for Prolia, SB16, which Samsung Bioepis applied on the 1st. Prolia developed by Amgen was approved in Korea in September 2014. It is
- Product
- COVID-19 vaccine almost there, how about cost-effectiveness?
- by Choi,sun Dec 7, 2020 06:05am
- The anticipation for the COVID-19 vaccines in development is soaring as a number of global pharmaceutical companies have announced successful clinical trial results. The health authority and the public would closely follow the vaccines’ further development to confirm their effect, safety and reasonable pricing. ▲The COVID-19 vaccine
- Company
- Ninlaro starts pricing negotiation after three long years
- by Eo, Yun-Ho Dec 4, 2020 05:55am
- An oral multiple myeloma treatment, Ninlaro is initiating the drug pricing negotiation to seek for the National Health Insurance (NHI) reimbursement. The pharmaceutical industry sources reported the drug has started the pricing negotiation with the National Health Insurance Service (NHIS) on the only oral option in multiple myeloma treat
- Opinion
- [Reporter’s View] Haste makes waste
- by Dec 4, 2020 05:55am
- The commercialization of the COVID-19 vaccine is approaching. The UK has already announced that the Pfizer vaccine will be approved for emergency use for the first time in the world and will be supplied early next week. Excluding vaccines from Russia and China that are not internationally recognized, this is the fastest action. The British go
